Banner

Joseph R. Volpicelli, MD, PhD

home / authors / joseph-r-volpicelli-md-phd

Joseph R. Volpicelli, MD, PhD, is a scientist-clinician with over 40 years of experience specializing in addiction psychiatry. He is executive director of the Institute of Addiction Medicine. His early work led to the approval of naltrexone to treat alcohol dependence; it was the first new medication to be FDA approved for this condition in nearly 50 years.

Articles

Joseph R. Volpicelli, MD, PhD © The Institute of Addiction Medicine

Alcohol use disorder is a medical condition — it’s time we treated it like one

Joseph R. Volpicelli, MD, PhD
May 5th 2025

Primary care physicians are often in the best position to identify and treat patients with AUD.

The risks of teen drinking and the role of family medicine physicians

The risks of teen drinking and the role of family medicine physicians

Joseph R. Volpicelli, MD, PhD
April 24th 2025

Teen drinking poses serious risks to adolescent health, affecting brain development and increasing addiction potential. There are effective strategies to address this issue.

aud alcohol use disorder man chained to bottle: © New Africa - stock.adobe.com

Looking back – and ahead – on the 30th anniversary of FDA approval for naltrexone as a treatment for alcohol use disorder

Joseph R. Volpicelli, MD, PhD
June 12th 2024

Medication-assisted treatment (MAT) is an effective treatment for AUD, but it remains underutilized by the medical community.

Latest Updated Articles

President Donald J. Trump © Courtesy of the Library of Congress Prints and Photographs Division
Published: March 3rd 2025 | Updated: April 3rd 2025
Trump tariffs on imports and effects on health care, explained
obesity bariatric surgery files: © Olivier Le Moal - stock.adobe.com
Published: January 27th 2025 | Updated: January 29th 2025
The Weight Loss Drug Revolution: GLP-1 RA drugs inspire new excitement for metabolic bariatric surgeons
semaglutide weight loss concept: © millaf - stock.adobe.com
Published: January 27th 2025 | Updated: January 29th 2025
The Weight Loss Drug Revolution: Helping patients avoid phony medicine scams
OmniVue Lens System: ©Atia Vision
Published: May 20th 2025 | Updated: May 24th 2025
Atia Vision receives FDA approval to begin clinical trial of novel intraocular lens
Biden prostate cancer diagnosis: Treatment options
Published: May 19th 2025 | Updated: May 24th 2025
Biden prostate cancer diagnosis: Treatment options
Biden prostate cancer diagnosis: Surgerical options, and discovering the disease
Published: May 19th 2025 | Updated: May 24th 2025
Biden prostate cancer diagnosis: Surgerical options, and discovering the disease